122 related articles for article (PubMed ID: 27005521)
1. Cost Recommendation under Uncertainty in IQWiG's Efficiency Frontier Framework.
Corro Ramos I; Lhachimi SK; Gerber-Grote A; Al MJ
Med Decis Making; 2017 Feb; 37(2):162-172. PubMed ID: 27005521
[TBL] [Abstract][Full Text] [Related]
2. The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options.
Mühlbacher AC; Sadler A
Value Health; 2017 Feb; 20(2):266-272. PubMed ID: 28237207
[TBL] [Abstract][Full Text] [Related]
3. [The Probabilistic Efficiency Frontier: A Value Assessment of Treatment Options in Hepatitis C].
Mühlbacher AC; Sadler A
Gesundheitswesen; 2019 Jan; 81(1):e21-e32. PubMed ID: 28628931
[TBL] [Abstract][Full Text] [Related]
4. Communicating the parameter uncertainty in the IQWiG efficiency frontier to decision-makers.
Stollenwerk B; Lhachimi SK; Briggs A; Fenwick E; Caro JJ; Siebert U; Danner M; Gerber-Grote A
Health Econ; 2015 Apr; 24(4):481-90. PubMed ID: 24590819
[TBL] [Abstract][Full Text] [Related]
5. Drug pricing and control of health expenditures: a comparison between a proportional decision rule and a cost-per-QALY rule.
Gandjour A
Int J Health Plann Manage; 2015; 30(4):395-402. PubMed ID: 24789123
[TBL] [Abstract][Full Text] [Related]
6. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
Siebert U; Rochau U; Claxton K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
[TBL] [Abstract][Full Text] [Related]
7. Determining the price for pharmaceuticals in Germany: comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelor.
Gandjour A; Gafni A; Schlander M
Expert Rev Pharmacoecon Outcomes Res; 2014 Feb; 14(1):123-9. PubMed ID: 24354766
[TBL] [Abstract][Full Text] [Related]
8. Germany's decision rule for setting ceiling prices of drugs: a comparative analysis with other decision rules.
Gandjour A
Appl Health Econ Health Policy; 2011 Mar; 9(2):65-71. PubMed ID: 21332250
[TBL] [Abstract][Full Text] [Related]
9. Presenting Germany's drug pricing rule as a cost-per-QALY rule.
Gandjour A
Health Care Manag Sci; 2012 Jun; 15(2):103-7. PubMed ID: 22187356
[TBL] [Abstract][Full Text] [Related]
10. A theoretical and empirical investigation into the willingness-to-pay function for new innovative drugs by Germany's health technology assessment agency (IQWiG).
Gandjour A
Health Serv Manage Res; 2013 Nov; 26(4):103-9. PubMed ID: 25595007
[TBL] [Abstract][Full Text] [Related]
11. [Comments by the Working Group for Methods of Economic Evaluation in Health Care (AG MEG) to IQWiG's Draft Guidelines "Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System"].
Krauth C; John J; Aidelsburger P; Brüggenjürgen B; Hansmeier T; Hessel F; Kohlmann T; Moock J; Rothgang H; Schweikert B; Seitz R; Wasem J;
Gesundheitswesen; 2008 Jun; 70(6):e1-16. PubMed ID: 18661452
[TBL] [Abstract][Full Text] [Related]
12. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
13. Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWiG.
Gandjour A
BMC Health Serv Res; 2020 Apr; 20(1):343. PubMed ID: 32321496
[TBL] [Abstract][Full Text] [Related]
14. [Should IQWiG revise its methods of cost-effectiveness analysis in order to comply with more widely accepted health economical evaluation standards?].
Lübbe W
Dtsch Med Wochenschr; 2010 Mar; 135(12):582-5. PubMed ID: 20234995
[TBL] [Abstract][Full Text] [Related]
15. The efficiency frontier approach to economic evaluation of health-care interventions.
Caro JJ; Nord E; Siebert U; McGuire A; McGregor M; Henry D; de Pouvourville G; Atella V; Kolominsky-Rabas P
Health Econ; 2010 Oct; 19(10):1117-27. PubMed ID: 20575151
[TBL] [Abstract][Full Text] [Related]
16. Probabilistic analysis and computationally expensive models: Necessary and required?
Griffin S; Claxton K; Hawkins N; Sculpher M
Value Health; 2006; 9(4):244-52. PubMed ID: 16903994
[TBL] [Abstract][Full Text] [Related]
17. Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison.
Wolff HB; Qendri V; Kunst N; Alarid-Escudero F; Coupé VMH
Med Decis Making; 2022 Oct; 42(7):956-968. PubMed ID: 35587181
[TBL] [Abstract][Full Text] [Related]
18. The German method for setting ceiling prices for drugs: in some cases less data are required.
Gandjour A; Gafni A
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):403-9. PubMed ID: 21831020
[TBL] [Abstract][Full Text] [Related]
19. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM
Value Health; 2005; 8(1):32-46. PubMed ID: 15841892
[TBL] [Abstract][Full Text] [Related]
20. Opportunity costs and uncertainty in the economic evaluation of health care interventions.
Sendi P; Gafni A; Birch S
Health Econ; 2002 Jan; 11(1):23-31. PubMed ID: 11788979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
